Fig. 1 · Structure
Documents & Downloads
Nafazatrom
Cardioprotective Agent
Nafazatrom is an orally active cardioprotective agent primarily targeting neutrophil function. It exhibits dose-dependent inhibition of neutrophil aggregation, superoxide anion production, and arachidonic acid metabolism, contributing to its cardioprotective effects. In preclinical studies, Nafazatrom (10 mg/kg, po) significantly reduced infarct size and arrhythmias in a dog ischemia-reperfusion model, while preserving myocardial function without impacting hemodynamics. This compound is valuable for research applications focused on ischemic heart disease and the mechanisms underlying cardiac injury and recovery.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 59040-30-1 |
| Applications | Cardioprotective Agent |
| Formula | C16H16N2O2 |
| Molecular Weight | 268.31 |
| Synonyms | Bay g 6575 |
| SMILES | O=C1N(N=C(C1)C)CCOC2=CC=C3C=CC=CC3=C2 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.